Article
Rheumatology
Allen Anandarajah, Caroline Thirukumaran, Katherine McCarthy, Sean McMahon, Changyong Feng, Christopher Ritchlin
Summary: By studying a group of high-need, high-cost patients with lupus, researchers found that these patients accounted for the majority of hospitalizations and medical costs. The clinical and social factors of this group were significantly different from other lupus patients, particularly in terms of blood indicators and social backgrounds.
ARTHRITIS CARE & RESEARCH
(2022)
Review
Immunology
Christopher Ritchlin
Summary: This article discusses the plasticity of the immune response in PsA, focusing on the importance of therapeutic targets including Th17 cells, monocytes, and CD8+ T resident cells. Additionally, it examines the effects of cytokines on tissue populations and new data on the interaction between immune cells and tissue resident cells in PsA.
SEMINARS IN IMMUNOPATHOLOGY
(2021)
Editorial Material
Rheumatology
Jose U. Scher, Alexis Ogdie, Joseph F. Merola, Christopher Ritchlin
ARTHRITIS & RHEUMATOLOGY
(2021)
Review
Dermatology
Di Yan, Johann E. Gudjonsson, Stephanie Le, Emanual Maverakis, Olesya Plazyo, Christopher Ritchlin, Jose U. Scher, Roopesh Singh, Nicole L. Ward, Stacie Bell, Wilson Liao
Summary: Psoriasis is a chronic inflammatory condition characterized by systemic immune dysregulation. Recent advances in genetics, microbiology, immunology, and mouse models have shed light on the complex interplay between heritable and microenvironmental factors in driving psoriatic inflammation. These scientific advancements have paved the way for a more personalized approach to treating psoriatic disease.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Article
Rheumatology
Christopher T. Ritchlin, Philip J. Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F. Merola, Iain B. McInnes, Atul Deodhar
Summary: The study evaluated the efficacy of guselkumab in PsA patients and found that both Q4W and Q8W treatments resulted in robust and sustained improvements in signs and symptoms across subgroups defined by diverse baseline characteristics.
Article
Rheumatology
Ananta Paine, Paul S. S. Brookes, Soumyaroop Bhattacharya, Dongmei Li, Maria De La Luz Garcia-Hernandez, Francisco Tausk, Christopher Ritchlin
Summary: We found differences in serum metabolites between PsA patients, psoriasis patients, and healthy controls. Differential abundance of bile acids, purines, pyrimidines, glutathione, lipids, and amino acid metabolites were observed in these three groups. Differences were also noted between psoriasis patients who progressed and those who did not progress to PsA. Decreased bile acid and butyrate levels and increased guanine levels in psoriasis patients at risk for PsA were particularly significant and may be reflective of gut microbial dysbiosis and dysregulated hepatic metabolism, leading to altered immune cell proliferation and enhanced cytokine expression.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Medicine, Research & Experimental
Roberta G. Marangoni, Poulami Datta, Ananta Paine, Stacey Duemmel, Marc Nuzzo, Laura Sherwood, John Varga, Christopher Ritchlin, Benjamin D. Korman
Summary: Thy-1 expression is significantly increased in the skin of patients with systemic sclerosis and is correlated with the severity of skin involvement. Thy-1 plays a critical regulatory role in the onset and progression of skin fibrosis. Additionally, Thy-1 may serve as a biomarker for evaluating skin fibrosis.
Article
Medicine, Research & Experimental
Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Desiree van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P. Kollmeier, Proton Rahman
Summary: Guselkumab shows efficacy in reducing radiographic progression in patients with active PsA. The APEX trial further evaluates the impact of guselkumab on patients with active PsA and known risk factors for radiographic progression.
Review
Rheumatology
H. Mark Kenney, Yue Peng, Karen L. de Mesy L. Bentley, Lianping Xing, Christopher T. Ritchlin, Edward M. Schwarz
Summary: Lymphatic muscle cell contractility and coverage are crucial for effective lymphatic drainage and tissue homeostasis. However, the fundamental role of these cells is still poorly understood due to their unique characteristics and difficulties in direct investigation. Further research is needed to uncover the origins, investiture, and maintenance of lymphatic muscle cells, as well as potential therapeutic strategies for controlling lymphatic contractility and drainage.
CURRENT RHEUMATOLOGY REVIEWS
(2023)
Article
Biochemistry & Molecular Biology
Kelly L. Hamilton, Amanda A. Greenspan, Alan J. Shienbaum, Bradford D. Fischer, Andrea Bottaro, Gary S. Goldberg
Summary: This study found that MASL, which targets PDPN, can be administered orally to ameliorate joint malformation and increase velocity of movement in TNF-Tg mouse model. These results support the consideration of MASL as a potential treatment for rheumatoid arthritis.
BIOCHEMISTRY AND BIOPHYSICS REPORTS
(2022)
Editorial Material
Rheumatology
Ying-Ying Leung, Arthur Kavanaugh, Christopher T. Ritchlin
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Christopher T. Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell
Summary: This study evaluated the efficacy and safety of guselkumab, an interleukin-23p19-subunit inhibitor, in patients with active psoriatic arthritis (PsA) who had previously used a tumor necrosis factor inhibitor (TNFi). The results showed that guselkumab provided sustained improvements across multiple domains in both TNFi-naive and TNFi-experienced patients with active PsA, and TNFi-naive patients were more likely to achieve treatment goals related to physical function and pain.
ACR OPEN RHEUMATOLOGY
(2023)
Article
Rheumatology
Christopher T. Ritchlin, Laura C. Coates, Iain B. Mcinnes, Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B. M. Landewe
Summary: The long-term efficacy and safety of Bimekizumab (BKZ) in patients with psoriatic arthritis (PsA) was evaluated. The results showed that the efficacy of BKZ was sustained from Week 16 to Week 52, and patients who switched to BKZ treatment demonstrated similar efficacy to those who received BKZ continuously. BKZ treatment was well tolerated without any new safety signals.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Lihi Eder, Ker-Ai Lee, Vinod Chandran, Jessica Widdifield, Aaron M. Drucker, Christopher Ritchlin, Cheryl F. Rosen, Richard J. Cook, Dafna D. Gladman
Summary: The study aimed to develop a risk prediction model for psoriasis patients to predict their risk of developing psoriatic arthritis (PsA) and evaluate its performance. The results showed that using readily available clinical variables, the development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron
Summary: This study aimed to evaluate gene expression in the blood of patients with psoriatic arthritis (PsA) compared to healthy controls and identify changes associated with the treatment of guselkumab. The results showed dysregulation of immune cell profiles in the blood of PsA patients, which were partially normalized after guselkumab treatment.
ACR OPEN RHEUMATOLOGY
(2023)